Red-blood-cell alloimmunisation in relation to antigens' exposure and their immunogenicity: a cohort study

The Lancet Haematology

Volumn 3, Issue 6, 2016, Pages e284-e292

  Evers, Dorothea ^a,b   Middelburg, Rutger A ^a,b   de Haas, Masja ^a,b,c   Zalpuri, Saurabh ^a   de Vooght, Karen M K ^d   van de Kerkhof, Daan ^e   Visser, Otto ^f   Péquériaux, Nathalie C ^g   Hudig, Francisca ^h   Schonewille, Henk ^a   Zwaginga, Jaap Jan ^a,b   van der Bom, Johanna G ^a,b  

^a SANQUIN RESEARCH   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c CENTRAL LABORATORY   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e CATHARINA HOSPITAL   (Netherlands)

^f VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^g JEROEN BOSCH HOSPITAL   (Netherlands)

^h HAGA HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY; ERYTHROCYTE ANTIGEN; BLOOD GROUP ANTIGEN;

ADULT; ALLOIMMUNIZATION; ANTIBODY RESPONSE; ARTICLE; COOMBS TEST; ERYTHROCYTE TRANSFUSION; FEMALE; FOLLOW UP; HUMAN; IMMUNOGENICITY; INCIDENCE; MAJOR CLINICAL STUDY; POST HOC ANALYSIS; PRIORITY JOURNAL; ADOLESCENT; AGED; BLOOD; BLOOD GROUP INCOMPATIBILITY; BLOOD GROUP TYPING; BLOOD TRANSFUSION REACTION; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; IMMUNOLOGY; INFANT; MALE; MIDDLE AGED; NETHERLANDS; PRESCHOOL CHILD; PROCEDURES; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLOOD GROUP ANTIGENS; BLOOD GROUP INCOMPATIBILITY; BLOOD GROUPING AND CROSSMATCHING; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; ERYTHROCYTE TRANSFUSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; INFANT; ISOANTIBODIES; MALE; MIDDLE AGED; NETHERLANDS; PROGNOSIS; SURVIVAL RATE; TRANSFUSION REACTION; YOUNG ADULT;

EID: 84975127015     PISSN: None     EISSN: 23523026     Source Type: Journal    
DOI: 10.1016/S2352-3026(16)30019-9     Document Type: Article

References (33)

1. 1 TRIP (Transfusion and transplantation Reactions In Patients). TRIP Hemovigilance report. https://www.tripnet.nl/pages/nl/documents/TRIP2014Hemovigilantie.pdf, 2013 (accessed Nov 26, 2015).
2. 2 SHOT (Serious Hazards Of Transfusion). SHOT report. http://www.shotuk.org/shot-reports/report-summary-supplement-2014, 2014 (accessed Nov 26, 2015).
3. 3 CBO. CBO blood transfusion guideline. http://www.sanquin.nl/repository/documenten/en/prod-en-dienst/287294/blood-transfusion-guideline.pdf, 2011 (accessed Aug 1, 2015).
4. 4 Giblett, ER, A critique of the theoretical hazard of inter vs. intra-racial transfusion. Transfusion 1 (1961), 233–238.
5. 5 Schonewille, H, van de Watering, LM, Loomans, DS, Brand, A, Red blood cell alloantibodies after transfusion: factors influencing incidence and specificity. Transfusion 46 (2006), 250–256.
6. 6 Tormey, CA, Stack, G, Immunogenicity of blood group antigens: a mathematical model corrected for antibody evanescence with exclusion of naturally occurring and pregnancy-related antibodies. Blood 114 (2009), 4279–4282.
7. 7 Winters, JL, Pineda, AA, Gorden, LD, et al. RBC alloantibody specificity and antigen potency in Olmsted County, Minnesota. Transfusion 41 (2001), 1413–1420.
8. 8 TRIX register. Dutch transfusion register for irregular antibodies. http://www.sanquin.nl/producten-diensten/diagnostiek/trix (accessed Aug 21, 2015; in Dutch).
9. 9 Strauss, RG, Cordle, DG, Quijana, J, Goeken, NE, Comparing alloimmunization in preterm infants after transfusion of fresh unmodified versus stored leukocyte-reduced red blood cells. J Pediatr Hematol Oncol 21 (1999), 224–230.
10. 10 Reid, ME, Lomas-Francis, C, Olsson, ML, The blood group antigen factsbook, 2nd edn., 2004, Elsevier Academic Press, San Diego.
11. 11 Frohn, C, Dümbgen, L, Brand, JM, Görg, S, Luhm, J, Krichner, H, Probability of anti-D development in D- patients receiving D+ RBCs. Transfusion 43 (2003), 893–898.
12. 12 Gunson, HH, Stratton, F, Cooper, DG, Rawlinson, VI, Primary immunization of Rh-negative volunteers. Br Med J 1 (1970), 593–595.
13. 13 Vamvakas, EC, Pineda, AA, Reisner, R, Santrach, PJ, Moore, SB, The differentiation of delayed hemolytic and delayed serologic transfusion reactions: incidence and predictors of hemolysis. Transfusion 35 (1995), 26–32.
14. 14 Bowman, JM, Pollock, J, Maternal CW alloimmunization. Vox Sang 64 (1993), 226–230.
15. 15 Verduin, EP, Brand, A, Middelburg, RA, Schonewille, H, Female sex of older patients is an independent risk factor for red blood cell alloimmunization after transfusion. Transfusion 55 (2015), 1478–1485.
16. 16 Schonewille, H, Haak, HL, van Zijl, AM, RBC antibody persistence. Transfusion 40 (2000), 1127–1131.
17. 17 Tormey, CA, Stack, G, The persistence and evanescence of blood group alloantibodies in men. Transfusion 49 (2009), 505–512.
18. 18 Koelewijn, JM, Vrijkotte, TG, van der Schoot, CE, Bonsel, GJ, de Haas, M, Effect of screening for red cell antibodies, other than anti-D, to detect hemolytic disease of the fetus and newborn: a population study in the Netherlands. Transfusion 48 (2008), 941–952.
19. 19 Lang, TJ, Estrogen as an immunomodulator. Clin Immunol 113 (2004), 224–230.
20. 20 Wayman, JC, Multiple imputation for missing data: what is it and how can I use it? Paper presented at the 2003 Annual Meeting of the Maerican Educational Research Association, Chicago, IL. http://www.csos.jhu.edu/contact/staff/jwayman_pub/wayman_multimp_aera2003.pdf (accessed April 15, 2016).
21. 21 Schafer, JL, Graham, JW, Missing data: our view of the state of the art. Psychol Methods 7 (2002), 147–177.
22. 22 Donders, AR, van der Heijden, GJ, Stijnen, T, Moons, KG, Review: a gentle introduction to imputation of missing values. J Clin Epidemiol 59 (2006), 1087–1091.
23. 23 Atsma, F, Veldhuizen, I, de Vegt, F, Doggen, C, de Kort, W, Cardiovascular and demographic characteristics in whole blood and plasma donors: results from the Donor InSight study. Transfusion 51 (2011), 412–420.
24. 24 Statline, Statististics, Heerlen/The Hague The Netherlands. http://statline.cbs.nl (accessed Nov 26, 2015).
25. 25 Yazdanbakhsh, K, Ware, RE, Noizat-Pirenne, F, Red blood cell alloimmunization in sickle cell disease: pathophysiology, risk factors, and transfusion management. Blood 120 (2012), 528–537.
26. 26 Zimring, JC, Stowell, SR, Johnsen, JM, Hendrickson, JE, Effects of genetic, epigenetic, and environmental factors on alloimmunization to transfused antigens: current paradigms and future considerations. Transfus Clin Biol 19 (2012), 125–131.
27. 27 Zimring, JC, Hendrickson, JE, The role of inflammation in alloimmunization to antigens on transfused red blood cells. Curr Opin Hematol 15 (2008), 631–635.
28. 28 Zalpuri, S, Zwaginga, JJ, van der Bom, JG, Risk factors for alloimmunisation after red blood cell transfusions (R-FACT): a case cohort study. BMJ Open, 2, 2012, e001150.
29. 29 Zalpuri, S, Evers, D, Zwaginga, JJ, et al. Immunosuppressants and alloimmunization against red blood cell transfusions. Transfusion 54 (2014), 1981–1987.
30. 30 Geoff, Daniels, Human Blood Groups, 3rd ed., 2013, Wiley-Blackwell, Chichester UK.
31. 31 Zalpuri, S, Middelburg, RA, Schonewille, H, et al. Intensive red blood cell transfusions and risk of alloimmunization. Transfusion 54 (2014), 278–284.
32. 32 Anstee, DJ, Goodbye to agglutination and all that?. Transfusion 45 (2005), 652–653.
33. 33 Avent, ND, Martinez, A, Flegel, WA, et al. The BloodGen project: toward mass-scale comprehensive genotyping of blood donors in the European Union and beyond. Transfusion 47 (2007), 40S–46S.